TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03827681

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans Intrahepatic Portosystemic Shunt
Description: * The most common approach is through the right internal jugular approach.~* After infiltrating the puncture site with 2% lignocaine and puncturing the vein a guide wire is advanced into the IVC followed by a 9F/10F vascular sheath.~* A wedged venogram is performed with a peripherally placed hepatic vein catheter, which may identify a portion of the portal vein to facilitate subsequent puncture.'~* A stiff guide wire is then passed through the catheter and the vascular sheath is advanced into the right hepatic vein. With the vascular sheath in place a rigid needle with 15-20 degrees of distal angulation is advanced over the guide wire and through the vascular sheath to enter the hepatic vein.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self Expanding Metallic Stent
Description: * At upper endoscopy, a 0.35 Superstiff radiological guidewire with a soft tip (supplied with the stent insertion kit) is delivered into the stomach under direct vision and the endoscope is removed.~* The stent delivery device is then advanced over the guidewire into the stomach, and the distal portion of the stent delivery system is withdrawn to allow inflation of the gastric balloon.~* The gastric balloon is then inflated with 100 mL of air, and the whole delivery system is withdrawn until resistance is felt, which signifies that the balloon is impacting at the cardia, thus anchoring the distal end of the stent during deployment.~* After stent deployment, the gastric balloon is deflated and the stent delivery system is withdrawn. The stent is then examined endoscopically. When deployed, the stent is 135 mm long and 25 mm wide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasoactive Agent
Description: Vasoactive Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasoactive Agent
Description: Vasoactive Agent
Study: NCT00661557

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal vaccine GSK134612 (Nimenrix)
Description: one dose, as intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612 (Nimenrix)
Description: one dose, as intramuscular injection
Study: NCT02757053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian Cap
Description: The Guardian Cap is a third party add-on device attached to the facemask of a football helmet that covers the outside of the helmet with a soft material to reduce the initial impact severity, thus reducing the forces transmitted to the brain
Study: NCT00428246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paricalcitol
Description: 1 mcg or 2 mcg for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paricalcitol
Description: 1 mcg or 2 mcg for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04148183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin group
Description: We add treatment with Metformin (850 mg/day), treatment was administered for 8 weeks
Study: NCT01474174

Intervention type: BIOLOGICAL
Intervention: trivalent influenza vaccine
Description: Given IM
Study: NCT03034577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Neostigmine 50 micrograms/kg coupled with atropine 20 micrograms/kg or glycopyrrolate 5 micrograms/kg, to a maximum dose of neostigmine of 5.0 mg. The neostigmine should not be administered until the TOF has at least 3 twitches present.
Study: NCT02897427

Intervention type: OTHER
Intervention: Biomarker Analysis
Description: Complete HPV testing
Study: NCT01474174

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02576847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omiganan
Description: Topical gel
Study: NCT02897427

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and oral gargle samples

Intervention type: PROCEDURE
Intervention: Ultrasonography
Description: Undergo transcervical ultrasonography
Study: NCT00060450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitric oxide for inhalation
Description: Either 10 or 20 ppm of inhaled nitric oxide for 24 hour post transplant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gas will be given at 10 or 20 ppm for 24 hours post transplant
Study: NCT04357626

Intervention type: OTHER
Intervention: Inpatient Rehabilitation
Description: Observational electronic records review study during inpatient rehabilitation
Study: NCT02012491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Study: NCT04625543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab Injection plus Paclitaxel and Cisplatin
Description: Paclitaxel 150mg/m2 on day 1, every 3 weeks, for two cycles; Cisplatin 70mg/m2 on day 1, every 3 weeks, for two cycles; Sintilimab Injection 200mg on day 22; 4-6 weeks after completion of preoperative therapy, Mckeown esophagectomy will be performed if there is no contraindication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel and Cisplatin
Description: Paclitaxel 150mg/m2 on day 1, every 3 weeks, for two cycles; Cisplatin 70mg/m2 on day 1, every 3 weeks, for two cycles; 4-6 weeks after completion of preoperative therapy, Mckeown esophagectomy will be performed if there is no contraindication.
Study: NCT01053208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen and Diphenhydramine Citrate
Description: Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen and Diphenhydramine Citrate
Description: Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
Study: NCT03834064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral health promotion strategy
Description: The proposed intervention is comprised of four components : (a) planned action including a behavioral contract Activity 1) with caregivers and action planning for oral health (Activity 2), (b) caregiver capacity building with didactic training (Activity 3), observational learning and caregiver practice (Activity 4); (c) environmental adaptations with location of oral health activities and reminder posters - physical environment (Activity 5) and administrative oral health support- (social environment (Activity 6); and (d) reinforcement with caregiver coaching (Activity 7).
Study: NCT00074035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentostatin
Description: 4 mg/sq m IV infusion over 20-30 min q 2 weeks
Study: NCT04144842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATOR-1017
Description: ATOR-1017 is a human monoclonal antibody targeting 4-1BB (CD137)
Study: NCT01327326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: Oral, 50 mg, 1 Time Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: Oral, 50 mg, 1 Time Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral, 1 Time Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral, 1 Time Dose
Study: NCT03375619

Intervention type: OTHER
Intervention: Long-Term Follow-Up of Participants who Received CAR-T cells
Description: No study drug is administered in this study. Participants who received CAR-T cells in a previous trial will be evaluated in this trial for long-term safety and efficacy.
Study: NCT04148183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone group
Description: we add Rosiglitazone (4 mg/day), treatment was administered for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: We add Placebo, treatment was administered for 8 weeks
Study: NCT01840683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)
Study: NCT03037684

Intervention type: DIAGNOSTIC_TEST
Intervention: neurophysiology
Description: electrophysiologic measurements of peripheral nerves

Intervention type: DIAGNOSTIC_TEST
Intervention: neurophysiology
Description: electrophysiologic measurements of peripheral nerves
Study: NCT01035320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: After a placebo only run-in period patients (two groups) are treated with simvastatin + ezetimibe and simvastatin + placebo in a cross-over trial. Ezetimibe effects on top of simvastatin will be evaluated as the primary aim; simvastatin effects compared to run-in on placebo will be evaluated as a secondary aim.
Study: NCT02657720

Intervention type: DEVICE
Group type: OTHER
Intervention: Radical 7
Description: Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Radical 7 measures respiratory rate according to acoustic respiratory rate (RRa).

Intervention type: DEVICE
Group type: OTHER
Intervention: Capnostream20p
Description: Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Capnostream20p measures respiratory rate using capnography (RRetCO2).

Intervention type: DEVICE
Group type: OTHER
Intervention: PTAF2
Description: Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. PTAF2 measures respiratory rate using flow pressure (RRflow).
Study: NCT00417027

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Programmed Intermittent Epidural Bolus (PIEB)
Description: A commercial pump that can be programmed to administer intermittent boluses and patient controlled boluses does not exist. Two pumps were prepared for each subject with the same epidural solution. One pump was programmed to administer the programmed intermittent epidural bolus(PIEB). The second pump was programmed to administer patient controlled epidural analgesia (PCEA)with a dose of 5 mL delivered with a lockout of every 10 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Programmed Intermittent Epidural Bolus (PIEB)
Description: A commercial pump that can be programmed to administer intermittent boluses and patient controlled boluses does not exist. Two pumps were prepared for each subject with the same epidural solution. One pump was programmed to administer the programmed intermittent epidural bolus(PIEB). The second pump was programmed to administer patient controlled epidural analgesia (PCEA)with a dose of 5 mL delivered with a lockout of every 10 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Programmed Intermittent Epidural Bolus (PIEB)
Description: A commercial pump that can be programmed to administer intermittent boluses and patient controlled boluses does not exist. Two pumps were prepared for each subject with the same epidural solution. One pump was programmed to administer the programmed intermittent epidural bolus(PIEB). The second pump was programmed to administer patient controlled epidural analgesia (PCEA)with a dose of 5 mL delivered with a lockout of every 10 minutes.
Study: NCT03196791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Sodium
Description: 1. INDICATIONS AND USAGE BRIDION® is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. BRIDION (sugammadex) injection is a sterile, clear, colorless to slightly yellow-brown, non-pyrogenic aqueous solution intended for intravenous infusion.~2. DOSAGE AND ADMINISTRATION BRIDION (sugammadex) injection, for intravenous use, should be administered by trained healthcare providers familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents (NMBA) and neuromuscular block reversal agents.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Sodium
Description: 1. INDICATIONS AND USAGE BRIDION® is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. BRIDION (sugammadex) injection is a sterile, clear, colorless to slightly yellow-brown, non-pyrogenic aqueous solution intended for intravenous infusion.~2. DOSAGE AND ADMINISTRATION BRIDION (sugammadex) injection, for intravenous use, should be administered by trained healthcare providers familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents (NMBA) and neuromuscular block reversal agents.
Study: NCT03759769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheelchair simulator
Description: Computer application providing 3D first person view of a wheelchair, with six different activities: street crossing, entering an elevator, entering an adapted van, bathroom, shopping mall and supermarket

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video game
Description: 'Kart' driving video game
Study: NCT03595709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg)
Description: All eligible subjects will receive 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg) once daily for 24 weeks orally on empty stomach before bedtime. If the event of toxicity or tolerability issues requires a change from study drug, switching to the best available treatment will be recommended.
Study: NCT02743442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: da Vinci® Si™
Study: NCT01573247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKN-028
Description: Part 1 of the study is a sequential dose-escalation evaluation of AKN-028. Part 1 started as an accelerated intra-patient dose escalation design in one patient at a time (the N=1 portion), and has switched to standard 3 + 3 design with inter-cohort dose escalation when AUC of 12 μM\*hrs has been reached. Starting dose of AKN-028 was 60 mg twice a day.~During Part 2 of the study AKN-028 will be administered at the dose level selected in Part 1. Patients will be treated for a maximum of 3 cycles (first cycle of 14 days followed by 2 cycles of 21 days), with at least a 7-day treatment-free period between cycles. Patients with significant benefit after 3rd cycle may continue treatment at discretion of the investigator for as long as the patient continues to show significant benefit.
Study: NCT02541695

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: E. coli strain E1392-75-2A
Description: At study day 14, after a standardized evening meal and an overnight fast, subjects will receive a single oral dose of the attenuated diarrhoeagenic E. coli strain E1392-75-2A (dose will be either 1E10 CFU (n=22) or 5E10 CFU (n=22)). Oral challenge will occur at 10.00 AM. Under supervision of the project team, subjects will get a NaHCO3 solution (100 ml 2% NaHCO3) to neutralize the gastric acid. After 5 minutes, they get a fruit juice (100 ml) containing the attenuated diarrhoeagenic E. coli strain at the above-mentioned dose. Subjects go home, but are not allowed to drink or eat for 1 hour.~At study day 35, after a standardized evening meal and an overnight fast, all subjects will receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E. coli strain E1392-75-2A
Description: At study day 14, after a standardized evening meal and an overnight fast, subjects will receive a single oral dose of the attenuated diarrhoeagenic E. coli strain E1392-75-2A (dose will be either 1E10 CFU (n=22) or 5E10 CFU (n=22)). Oral challenge will occur at 10.00 AM. Under supervision of the project team, subjects will get a NaHCO3 solution (100 ml 2% NaHCO3) to neutralize the gastric acid. After 5 minutes, they get a fruit juice (100 ml) containing the attenuated diarrhoeagenic E. coli strain at the above-mentioned dose. Subjects go home, but are not allowed to drink or eat for 1 hour.~At study day 35, after a standardized evening meal and an overnight fast, all subjects will receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
Study: NCT01849939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabin (post-allograft immunosuppressive therapy modulation and DLI Mononuclear cells from allogenic blood)
Study: NCT02501109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Healthy volunteers will receive Aripiprazole Oral Soluble Fim(OSF) 10mg orally a single of dose within 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Healthy volunteers will receive Aripiprazole Oral Soluble Fim(OSF) 10mg orally a single of dose within 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Healthy volunteers will receive Aripiprazole Oral Soluble Fim(OSF) 10mg orally a single of dose within 28 days
Study: NCT02971514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flossing before Brushing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brushing before Flossing
Study: NCT04023994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7126209
Description: Participants will be administered single-ascending intravenous doses of RO7126209 with at least 2 weeks between each dose level. After the starting dose, the subsequent doses will be selected in an adaptive design. Sentinel dosing will be employed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7126209
Description: Participants will be administered single-ascending intravenous doses of RO7126209 with at least 2 weeks between each dose level. After the starting dose, the subsequent doses will be selected in an adaptive design. Sentinel dosing will be employed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7126209
Description: Participants will be administered single-ascending intravenous doses of RO7126209 with at least 2 weeks between each dose level. After the starting dose, the subsequent doses will be selected in an adaptive design. Sentinel dosing will be employed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7126209
Description: Participants will be administered single-ascending intravenous doses of RO7126209 with at least 2 weeks between each dose level. After the starting dose, the subsequent doses will be selected in an adaptive design. Sentinel dosing will be employed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7126209
Description: Participants will be administered single-ascending intravenous doses of RO7126209 with at least 2 weeks between each dose level. After the starting dose, the subsequent doses will be selected in an adaptive design. Sentinel dosing will be employed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered a single intravenous dose of matching placebo.
Study: NCT00677924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalutumumab
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalutumumab
Description: Solution for infusion
Study: NCT01169649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: MK-2206 will be given orally 200 mg qw as given in the prior Ph1 clinical trial that demonstrated safety, tolerability and adequate PK/PD values at this dose. Follow-up imaging scans will be performed every 12 weeks to evaluate response. Patients must take MK-2206 orally at least 2 hours before or 2 hours after food or a meal.
Study: NCT02917954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ePRO Tool Intervention
Description: The ePRO tool includes two features: 1) My Goal Tracker and 2) Health Journal. My Goal Tracker allows patients and providers to collaboratively create goal-oriented patient care-plans, and helps patients to track outcomes related to their goals using a mobile device. The Health Journal allows patients, their caregivers and primary care providers to monitor patients' symptoms and outcomes.
Study: NCT04382157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mablet 360 mg
Description: Slow-released magnesium hydroxide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01427803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium ER (BAYH6689)
Description: BAYH6689; oral tablet used as needed upon incidence of pain
Study: NCT00300092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cepahlexin (drug)
Description: Cephalexin 50 mg/kg divided 3 times daily for 7 days
Study: NCT04009967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg every three weeks for 3 cycles only
Study: NCT04362033

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Passive Leg Raising (PLR) and PEEP increment (PEEP)
Description: PLR: Fluid responsiveness maneuver which patient is positioned from 45 grade of semi-recumbent position to dorsal decubitus and the legs are raised at 45 grades; PEEP increment: Fluid responsiveness maneuver which consisted in increased the PEEP level 5 cmH2O above the mean airway pressure, patient is positioned in 45 grade of semi-recumbent position

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Passive Leg Raising (PLR) and PEEP increment (PEEP)
Description: PLR: Fluid responsiveness maneuver which patient is positioned from 45 grade of semi-recumbent position to dorsal decubitus and the legs are raised at 45 grades; PEEP increment: Fluid responsiveness maneuver which consisted in increased the PEEP level 5 cmH2O above the mean airway pressure, patient is positioned in 45 grade of semi-recumbent position
Study: NCT01088152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Celiac school
Description: Structured education of adult celiac patients at 10 sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care of celiac disease women
Description: Written information corresponding to that offered when seeking medical advice for well treated celiac disease in the primary care.
Study: NCT00811200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: three initial monthly intra vitreal injections with 0.5 mg ranibizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone acetonide
Description: at baseline one intra vitreal injection with 4.0 mg triamcinolone acetonide

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham
Description: at baseline one sham-injection
Study: NCT02269215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIII 890 CL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01151787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclobenzaprine hydrochloride
Description: 15mg daily for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo